文献速递类风湿关节炎脊柱关节炎

生物制剂减量策略:系统综述与临床医生视角

Dosing down with biologic therapies: a systematic review and clinicians' perspective.
PubMed 文献 · Rheumatology (Oxford) · 2017-01-01

结果显示停药后缓解通常难以维持,早期RA复发率48-54%、确立RA 2-84%、中轴型脊柱关节炎11-53%、PsA 44.9%,多数患者再治疗可恢复可接受疾病活动度。

要点

  • 停药后缓解难以持续,各病种复发/ flare率差异大
  • 多数患者再治疗可恢复可接受疾病活动度
  • 需更多研究了解减量策略对疗效、安全性和费用的长期影响

核心结论

  • 停用生物制剂后缓解通常不能维持,但再治疗多可恢复可接受疾病活动度。

主要发现

  • 停药后复发/ flare率:早期RA 48-54%,确立RA 2-84%,中轴型脊柱关节炎11-53%,PsA 44.9%。
  • 许多情况下再治疗可恢复可接受的疾病活动度。

临床怎么用

  • 临床可考虑对达到缓解/低疾病活动度的患者尝试生物制剂减量,但需警惕停药后复发。
  • 再治疗多可恢复疾病控制,减量策略需个体化权衡。

局限性

  • 需更多研究理解减量策略对疗效、安全性和费用的长期影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The effectiveness of biologic therapies now means that remission or low disease activity are realistic targets for treatment. However, after achieving remission/low disease activity, the next steps remain unclear. The aim of this publication was to conduct a broad systematic literature review to evaluate dosing down of biologics. After screening papers and abstracts for relevance and application of inclusion/exclusion criteria, a structured extraction process was used to collect information on the included studies. Fifty-two papers were included in the analysis across rheumatic disease. In patients who discontinue therapy, remission is not typically sustained, with reported rates of relapse and flare across early RA (48-54%), established RA (2-84%), axial spondyloarthritis (11-53%) and PsA (44.9%). In many cases, an acceptable disease activity can be regained upon retreatment. More research is needed to understand the long-term impacts of these strategies on efficacy, safety and cost.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Edwards CJ, Fautrel B, Schulze-Koops H, et al. Dosing down with biologic therapies: a systematic review and clinicians' perspective. Rheumatology (Oxford). 2017. PMID: 28339632. doi:10.1093/rheumatology/kew464

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。